Frontier Pharma Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation Analysis & Forecast.pdf

· The dominant dopamine agonists, ropinirole and pramipexole, are expected to trigger the
sales significantly. The increasing usage of Agilect, the MAO-B inhibitor, and the resurgence of
UCB’s Leganto/Neupro in the U.S. market with an even wider employment in the European
market are also projected to drive the market growth.
· In spite of the increased uptake of some key therapies currently functional in the market and
the announcement to launch 3 new agents (GlaxoSmithKline’s IPX-066, Newron
Pharmaceuticals’ safinamide, and Kyowa Hakko Kirin’s istradefylline) by 2020, the sales of
current agents and their impact on the market of emerging therapies is likely to be
suppressed by generic competition.
Send An Enquiry: http://www.mrrse.com/enquiry/131
Table of Contents:
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 Highly Innovative and Diverse Pipeline 5
2.2 Alignment of Innovation to Disease Processes and Genetics 5
2.3 Deals Landscape Present Substantial Investment Opportunities 5
3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 7